Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT Protocol: Talimogene Laherparepvec, Nivolumab and Trabectedin in Advanced Sarcoma
NCT03886311Phase 2Recruiting
- Sponsor
- Cancer Institute Medical Group
- Start
- May 2019
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies, Oncolytic Viruses, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec, nivolumab and trabectedin in sarcoma, desmoid tumor and chordoma, sponsored by Cancer Institute Medical Group. Primary endpoint: Progression-Free Survival at 12 months. Started May 2019; status: recruiting.
02
Drugs
03
Conditions
sarcomadesmoid tumorchordoma
Beyond the preview
Go deeper on NCT03886311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886311.